To provide the information your oncologist is not telling you or doesn't have the time to!
Explore the intricacies of pancreatic cancer in our dedicated ‘Pancreatic Cancer’ subcategory. Focused on providing valuable insights into this challenging and often complex form of cancer, our curated content covers a broad spectrum. Navigate through informative articles, expert perspectives, and the latest advancements in research and treatment options specific to pancreatic cancer. Whether you’re seeking information on early detection, treatment modalities, or supportive care strategies, our ‘Pancreatic Cancer’ subcategory serves as a reliable resource. Empowering individuals, caregivers, and healthcare professionals, we aim to foster awareness and understanding to navigate the unique challenges of pancreatic cancer. Join us on a journey toward informed decision-making and proactive pancreatic health within this specialized field of oncology.
On December 2, 2024, Novocure announced positive results from the Phase 3 PANOVA-3 trial, which evaluated Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel for unresectable, locally advanced pancreatic cancer. The trial demonstrated a statistically significant improvement in overall survival (OS), offering a new potential option for this challenging patient population. However, …
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri), marking a significant milestone in cancer care. This is the first approved systemic therapy targeting NRG1 gene fusions, a rare but actionable driver mutation in certain cancers. Zenocutuzumab-zbco is approved for adults with: This approval offers a new, precision-medicine option for patients with …
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
Pancreatic cancer is a highly aggressive form of cancer that often goes undetected until it reaches an advanced stage. To improve treatment outcomes, individuals must be aware of the early warning signs and seek medical attention promptly. This article aims to educate readers about the signs and symptoms of pancreatic cancer, emphasizing the importance of …
KRAS is a gene that plays a key role in the growth and division of cells. Mutations in the KRAS gene can cause cancer, and one particular mutation called KRAS G12C occurs in about 1-2% of pancreatic cancers and 2-4% of colon cancers. These mutations make the cancer resistant to certain treatment options and are …